Clinical Assessment - 26-Year-Old with Recurrent Obstruction + New Symptoms

Your Symptom Summary

Most Likely Diagnosis: Crohn's Disease (Inflammatory Bowel Disease)

• Recurrent obstruction - Crohn's causes progressive fibrostenosing narrowing (strictures) in the bowel wall. Early on, these cause intermittent obstruction episodes. As the disease advances, strictures worsen, and bowel obstruction becomes more frequent and severe.
• Bilious (yellow), foul-smelling vomiting - Feculent vomiting occurs when colonic disease fistulizes into the stomach or proximal bowel, or when bacterial overgrowth develops behind a stricture. Harrison's directly states: "Colonic disease may fistulize into the stomach or duodenum, causing feculent vomiting."
• Black stool (melena) with undigested particles - Melena means upper GI bleeding. In Crohn's disease, deep ulcers and inflammation can erode blood vessels causing bleeding. Undigested food particles in stool ("undigested particles") indicate severely impaired digestion and malabsorption.
• Diarrhea alongside obstruction - This seemingly contradictory combination is a hallmark of Crohn's. Harrison's explains: "Diarrhea is characteristic of active disease; its causes include bacterial overgrowth in obstructive stasis or fistulization, bile acid malabsorption, intestinal inflammation, and enteroenteric fistulas."
• Tenesmus (intense rectal/anal pain, urgent defecation) - This is a classic feature of Crohn's colitis (disease involving the large bowel or rectum), caused by decreased rectal compliance and severe inflammation.
• Age 26 - Crohn's disease has a peak onset between ages 15-35.

Other Diagnoses to Consider

Why This Is Urgent - Red Flag Symptoms

1. Active GI bleeding - melena is never normal; requires investigation to find and stop the bleeding source
2. Possible stricture with proximal bacterial overgrowth and feculent vomiting
3. Possible fistula formation (bowel-to-bowel connection) - a Crohn's complication
4. Malabsorption - undigested food particles suggest the intestine is not absorbing nutrients

What Tests Are Needed (for your doctor)

• Colonoscopy + ileoscopy - to look for Crohn's ulcers, strictures, colitis
• CT scan of abdomen/pelvis with contrast - to assess obstruction level, look for fistulas, abscesses
• Upper GI endoscopy - to identify the source of black stool/bleeding
• MRI enterography - detailed look at small bowel (Crohn's preferred imaging)
• Stool tests - calprotectin (inflammation marker), cultures, for occult blood
• Blood tests - CBC (anemia from bleeding), CRP/ESR (inflammation), B12, albumin, LFTs

Bottom Line

Important disclaimer: This is educational information only and does not replace professional medical evaluation. Please seek immediate medical care given these symptoms.

Crohn's Disease - Complete Treatment Guide

Step 1: Assess Disease Severity

1. Aminosalicylates (5-ASA)

• Drugs: Mesalamine (sulfasalazine)
• Used for mild colonic Crohn's only - limited role overall
• Evidence is weak; not effective for small bowel or severe disease
• Mainly used when other options are not available or as adjuncts

2. Corticosteroids - For Induction of Remission (NOT maintenance)

Conventional (systemic)

• Prednisone 40-60 mg/day, tapered over 6-12 weeks
• Response rate ~80% within the first month; up to 92% at 1 mg/kg/day
• Not for long-term use - they do NOT maintain remission and cause serious side effects (osteoporosis, diabetes, adrenal suppression)

Budesonide (preferred for ileocecal disease)

• 9 mg/day - controlled release in the ileocecal region
• ~90% first-pass liver metabolism = far fewer systemic side effects than prednisone
• Slightly less potent than prednisolone but much better tolerated
• Superior to placebo and mesalamine; used for mild-moderate ileocecal CD

Key point from Sleisenger & Fordtran: "Glucocorticoids are not effective as long-term therapy. A meta-analysis failed to detect benefit in prevention of relapse at 6, 12, or 24 months."

3. Immunomodulators - For Maintenance of Remission

Thiopurines: Azathioprine (AZA) / 6-Mercaptopurine (6-MP)

• AZA: 2-2.5 mg/kg/day; 6-MP: 1-1.5 mg/kg/day
• Slow onset - take 3-4 months to work; need steroid bridge during this period
• Highly effective for maintenance of remission (OR 2.32-3.32 vs placebo)
• ~50% of patients respond; of those, 50-65% maintain remission long-term
• Also used to reduce formation of anti-drug antibodies when combined with biologics
• Monitor: CBC, LFTs, check TPMT enzyme activity before starting (risk of toxicity)

Methotrexate (MTX)

• 25 mg IM/SC weekly for induction; 15 mg/week for maintenance
• Used when thiopurines fail or are not tolerated
• Requires folic acid supplementation to reduce toxicity
• Contraindicated in pregnancy (teratogenic)

4. Biologic Therapy - For Moderate-to-Severe or Refractory Disease

Anti-TNF Agents (First-Line Biologics)

• Infliximab: 81% response vs 17% placebo in landmark RCT; 39-45% in remission at 54 weeks on maintenance
• Highly effective for perianal fistulas (ACCENT II: 36% complete fistula closure vs 19% placebo)
• Early use gives much better results - response rates are higher when started within 2 years of diagnosis

Anti-Integrin Agents

• Vedolizumab (IV) - gut-selective anti-α4β7 integrin; approved for moderate-severe CD
• Blocks lymphocyte trafficking to the gut with minimal systemic immune suppression
• Safer immunologically than anti-TNF; preferred in patients with infection risk

Anti-IL-12/23 Agent

• Ustekinumab (IV then SC) - 6 mg/kg IV loading dose, then 90 mg SC every 8-12 weeks
• Approved for moderate-to-severe CD
• Effective in anti-TNF-experienced patients

Anti-IL-23 Agent (Newest)

• Risankizumab - anti-IL-23p19; FDA approved for CD
• Good efficacy data including in anti-TNF failure patients

5. Small Molecule Therapies (Oral - Newer Options)

JAK Inhibitors

• Upadacitinib (oral, selective JAK1 inhibitor) - approved for both UC and CD
  • Rapid clinical and endoscopic improvement; positive benefit/risk profile
• Tofacitinib - pan-JAK inhibitor; approved for UC; second-line after anti-TNF failure
• Safety note: JAK inhibitors carry increased risk of heart attack, stroke, blood clots, and cancers; use cautiously in patients over 50 or with cardiovascular risk

Ozanimod (S1P receptor modulator)

• Prevents lymphocyte trafficking; approved for UC currently

6. Combination Therapy - "Top-Down" Strategy

• 57% in steroid-free remission with combination vs 44% with infliximab alone vs 30% with AZA alone
• Mucosal healing occurred more often in the combination group
• Combining immunomodulators with biologics also reduces anti-drug antibody formation, maintaining drug effectiveness long-term

7. Nutritional Therapy

• Exclusive Enteral Nutrition (EEN) - as effective as glucocorticoids for inducing remission, especially in children
• Total Parenteral Nutrition (TPN) - for severe disease, bowel rest, or preoperative optimization
• Diet: maximize fiber (fruits and vegetables), limit refined carbohydrates, red/processed meat, animal fats
• Diets supported by evidence: Mediterranean diet, Specific Carbohydrate Diet, IBD Anti-Inflammatory Diet (IBD-AID)
• Replete deficiencies: Vitamin B12, folate, iron, Vitamin D, calcium, zinc, magnesium

8. Surgical Treatment

Indications for Surgery (Sabiston Textbook of Surgery):

• Bowel obstruction from fibrostenosing strictures (most common)
• Perforating disease - abscess or fistula not responding to medical therapy
• Symptomatic fistulas (enterocutaneous, ileal-sigmoid bypassing colon)
• Cancer or dysplasia in chronically diseased bowel
• Growth failure in children
• Failure of medical therapy

Surgical Options:

• Strictureplasty - widening of strictured segment without resection (bowel-preserving)
• Segmental bowel resection - removal of diseased segment with anastomosis
• Abscess drainage (percutaneous first, then surgical if needed)
• Preoperative prep: antibiotics, nutritional optimization, taper steroids, hold biologics before surgery, DVT prophylaxis

Treatment Algorithm Summary

MILD DISEASE
→ Budesonide (ileocecal) or 5-ASA (colonic)

MODERATE DISEASE
→ Prednisone (induction) + AZA/6-MP (maintenance)
→ If thiopurine fails → Methotrexate

MODERATE-SEVERE / REFRACTORY
→ Anti-TNF (Infliximab/Adalimumab) ± Thiopurine (combination preferred)
→ If anti-TNF fails → Vedolizumab, Ustekinumab, or Risankizumab
→ If biologic fails → Upadacitinib (JAK1 inhibitor)

COMPLICATIONS (obstruction, fistula, abscess)
→ Surgery

Monitoring & Follow-Up

• Regular colonoscopy to assess mucosal healing (treat-to-target)
• Monitor CRP/ESR, fecal calprotectin for inflammation
• Drug monitoring: thiopurine metabolite levels (6-TGN), anti-drug antibodies for biologics
• Vaccinations before starting immunosuppression (flu, pneumococcus, shingles before JAK inhibitors)
• Cancer surveillance colonoscopy after 8 years of colonic disease

Disclaimer: This information is educational. All treatment decisions must be made by a qualified gastroenterologist based on individual assessment.